MODIFICATION
A -- FDA_13-RFQ-1120926
- Notice Date
- 8/8/2013
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- 13-RFQ-1120926
- Archive Date
- 8/20/2013
- Point of Contact
- Aaron A. Glazier, Phone: 8705437577
- E-Mail Address
-
aaron.glazier@fda.hhs.gov
(aaron.glazier@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- The purpose of this amendment is to provide a response to the following vendor question posed on 8/7/13: "We interpret that the generic in question (Budeprion XL 300 mg) will not be part of the described study and that we will obtain clinical trial material directly from suppliers as part of the total cost of the study. Please confirm." Govt Response: Budeprion XL 300 mg will not be part of the study because it has been withdrawn from the market. The vendor should obtain clinical trial materials directly from suppliers as part of the total cost of the study. No extension to the bid deadline will be issued.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/13-RFQ-1120926/listing.html)
- Place of Performance
- Address: Contractor's Place of Business, United States
- Record
- SN03143203-W 20130810/130809000343-4eed8528a3b72813cd84b664acb5e9f4 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |